CXCR4 and early-onset autosomal dominant Alzheimer disease: The compound’s favorable ranking demonstrates the framework’s ability to identify repurposing opportunities for established drugs, with mechanisms relevant to Alzheimer’s disease pathogenesis through CXCR4-mediated modulation of chemokine signaling pathways implicated in neuroinflammation [61,62].